The earnings call highlighted strong revenue growth, particularly in the Cardiovascular and Electrophysiology segments, with significant contributions from geographic expansion and product line success. However, challenges such as the discontinuation of the ACURATE valve and slow growth in certain regions were noted.

Company Guidance -

Q3 2025

During the Boston Scientific Second Quarter 2025 Earnings Call, the company highlighted its strong financial performance and increased guidance for the year. Total company operational sales grew by 22% in Q2, with organic sales growth at 17%, exceeding the prior guidance range of 13% to 15%. Adjusted EPS for the quarter was $0.75, surpassing the expected range of $0.71 to $0.73. The company also raised its full-year organic growth guidance from 12%-14% to 14%-15% and adjusted EPS expectations to $2.95-$2.99, reflecting growth of 18%-19%. Regionally, the U.S. saw a 31% operational growth driven by the cardiovascular portfolio, while Asia Pacific grew by 15%. The Cardiovascular segment, led by high demand for FARAPULSE, WATCHMAN, and Complex PCI, was a significant contributor. Despite challenges, such as the worldwide discontinuation of the ACURATE valve, Boston Scientific maintained a positive outlook with plans for continued investment in R&D and strategic partnerships to fuel growth.

Strong Revenue Growth

Total company operational sales grew 22% and organic sales grew 17%, exceeding the high end of the guidance range of 13% to 15%.

Cardiovascular Segment Success

Cardiology sales grew 28%, driven by strong performance in Interventional Cardiology and WATCHMAN product lines.

WATCHMAN Segment Growth

WATCHMAN grew 28% this quarter, reflecting strong safety profile and expanded labeling, with significant uptake in concomitant procedures.

Geographic Expansion

Asia Pacific grew 15% operationally, with strong double-digit growth in Japan, China, and Australia, driven by FARAPULSE and IVUS.

Positive EPS Performance

Adjusted EPS of $0.75 grew 23%, exceeding the high end of guidance, driven by strong sales performance.

Electrophysiology Growth

Electrophysiology sales grew 94%, supported by the FARAPULSE launch and positive results from the ADVANTAGE AF trial.

Boston Scientific (BSX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BSX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 22, 2025	2025 (Q3)	0.71 / -	0.63	―	―	―
Jul 23, 2025	2025 (Q2)	0.72 / 0.75	0.62	20.97% (+0.13)
Apr 23, 2025	2025 (Q1)	0.67 / 0.75	0.56	33.93% (+0.19)
Feb 05, 2025	2024 (Q4)	0.66 / 0.70	0.55	27.27% (+0.15)
Oct 23, 2024	2024 (Q3)	0.59 / 0.63	0.5	26.00% (+0.13)
Jul 24, 2024	2024 (Q2)	0.58 / 0.62	0.53	16.98% (+0.09)
Apr 24, 2024	2024 (Q1)	0.51 / 0.56	0.47	19.15% (+0.09)
Jan 31, 2024	2023 (Q4)	0.51 / 0.55	0.45	22.22% (+0.10)
Oct 26, 2023	2023 (Q3)	0.48 / 0.50	0.43	16.28% (+0.07)
Jul 27, 2023	2023 (Q2)	0.49 / 0.53	0.44	20.45% (+0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BSX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 23, 2025	$103.16	$107.76	+4.46%
Apr 23, 2025	$95.05	$98.92	+4.07%
Feb 05, 2025	$103.54	$104.97	+1.38%
Oct 23, 2024	$88.01	$87.45	-0.64%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.